英国布里斯托大学孵化的AI生物科技初创公司CellVoyant日前宣布，已成功筹集到760万英镑的种子资金。该公司专注于利用人工智能成像技术，帮助干细胞疗法开发商更高效地制造新型治疗方案。此轮融资由Octopus Ventures领投，并得到了Horizons Ventures、Air Street Capital和Verve Ventures的参投。
CellVoyant的技术通过AI算法对细胞进行分析，能够大大提高干细胞疗法的开发速度和成功率。这对于医疗领域来说是一个巨大的进步，因为干细胞疗法被广泛认为是治疗多种疾病的新希望。
此轮融资的成功，不仅为CellVoyant提供了资金支持，也证明了投资者对AI技术在医疗领域应用的信心。随着技术的不断进步，未来我们或许能够看到更多利用AI技术开发的创新医疗解决方案。
英文标题：CellVoyant Secures £7.6 Million Seed Funding
英文关键词：Biotechnology, Artificial Intelligence, Stem Cell Therapy
英文新闻内容：
CellVoyant, an AI biotech startup incubated by the University of Bristol, has announced the successful fundraising of £7.6 million in seed funding. The company focuses on utilizing AI imaging technology to help stem cell therapy developers manufacture novel treatments more efficiently. This funding round was led by Octopus Ventures and supported by Horizons Ventures, Air Street Capital, and Verve Ventures.
CellVoyant’s technology uses AI algorithms to analyze cells, significantly increasing the speed and success rate of stem cell therapy development. This is a major breakthrough for the medical field, as stem cell therapy is widely regarded as a new hope for treating various diseases.
The success of this funding round not only provides financial support for CellVoyant but also demonstrates investors’ confidence in the application of AI technology in the medical sector. As technology continues to advance, we may see more innovative medical solutions developed using AI technology in the future.
【来源】https://sifted.eu/articles/ai-biotech-cellvoyant-raise
Views: 3